$365 Billion is the total value of Versant Venture Management, LLC's 9 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $177,224,616,000 | -30.8% | 4,205,615 | 0.0% | 48.60% | -37.0% | |
| ADVM | New | Adverum Biotechnologies, Inc. | $69,056,636,000 | – | 7,068,233 | +100.0% | 18.94% | – |
| AKRO | New | Akero Therapeutics, Inc. | $58,015,326,000 | – | 2,736,572 | +100.0% | 15.91% | – |
| VCYT | Veracyte, Inc. | $29,303,444,000 | -12.9% | 1,205,407 | 0.0% | 8.04% | -20.8% | |
| GRTS | Gritstone Oncology, Inc. | $18,059,047,000 | -35.1% | 3,102,929 | 0.0% | 4.95% | -40.9% | |
| OCUL | Ocular Therapeutix, Inc. | $10,966,151,000 | +25.3% | 2,215,384 | 0.0% | 3.01% | +14.0% | |
| CBAY | CymaBay Therapeutics, Inc. | $804,754,000 | -24.5% | 543,753 | 0.0% | 0.22% | -31.2% | |
| CLVS | Clovis Oncology, Inc. | $647,798,000 | -39.0% | 101,855 | 0.0% | 0.18% | -44.4% | |
| EYES | Sell | Second Sight Medical Products, Inc. | $558,635,000 | -83.3% | 561,612 | -87.5% | 0.15% | -84.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-04-28
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.